Dr. Versi is currently Clinical Associate Professor of OBGYN at Rutgers RWJ School of Medicine in New Jersey, USA and President of Versi Group LLC. He was previously Medical Head of Urology & Women’s Health at Pfizer and VP, Head of Medical Affairs at Yamanouchi Pharma America (Astellas) and Chief Medical Officer smaller pharma and device companies. He has been responsible for pre-clinical and clinical development and post registration studies for oxybuynin, tolterodine, tropism, solifenacin and duloxetine as well as some anti-incontinence devices. His research expertise includes pharmacology (drugs for overactive bladder, stress incontinence, menopause and contraception) investigative techniques and pathophysiology of lower urinary tract dysfunction and menopause that have resulted in over 100 scientific publications. He has practiced academic medicine in US and UK. He trained at the Universities of Oxford, Cambridge and London, and was Chief of Division at the Brigham & Women’s Hospital and Associate Professor at Harvard University. He is a member of the Royal College of Obstetricians and Gynecologists and has been Chairman of the Research Committee of the American Urogynecologic Society, Chairman of the Socio-economic Committee of the International Consultation on Incontinence, member of the expert advisory panel in Urogynecology for FIGO and several ad hoc committees for the NIH.